Melanoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Alerts
• Clinical Trials
• Forums

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
Conditions:   Triple Negative Breast Cancer;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma;   Lymphoma, Non-Hodgkin;   Mantle Cell Lymphoma;   Bladder Cancer;   Uveal Melanoma, Recurrent;   Cervix Cancer;   Carcinoma in Situ;   Head and Neck Squamous Cell Carcinoma;   Skin Cancer;   Metastatic Cancer;   Tumor, Solid;   Tumor Recurrence Interventions:   Drug: ONM-501;   Drug: Cemiplimab Sponsor:   OncoNano Medicine, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 1, 2023 Category: Research Source Type: clinical trials